Meda is no stranger to the M&A arena, last year inking a pact to buy Italy's Rottapharm. This time, though, it could wind up on the other side of the bargaining table.
After announcing a $2 billion manufacturing investment Wednesday--and launching a late-stage trial of its oral semaglutide drug to boot--the Danish drugmaker now says it's buying two private biopharma research companies specializing in diabetes and related metabolic problems.
Early this month, Horizon Pharma wrote to hostile target Depomed to get the ball rolling on requesting a special shareholders' meeting. And it's not happy about how that process has gone so far.
Greatbatch is snatching up Lake Region Medical for $1.73 billion to beef up its offerings and expand its global reach, months after the company announced it would spin off its neurostimulation unit to focus on building out its portfolio.
Friday, Mylan's shareholders will vote on whether the company should move ahead with its hostile bid for Perrigo. But Teva won't be among them, despite the fact that it built up a 4.61% Mylan stake when it was trying to buy the company earlier this year.
Serial buyer Allergan is getting ready to head back to the bargaining table, and there's plenty of buzz about who its next target will be. Who should it be, though, as far as FiercePharma readers are concerned? That's the question we posed last Tuesday, and since then, more than 500 of you have weighed in.
There are just three days left until Mylan's shareholders decide whether the company should push forward with its hostile pursuit of Perrigo. And just in case they do, Perrigo is making sure its own shareholders are ready to shoot it down.
Bill Ackman's relationship with Valeant has paid off big-time since the hedge fund manager first teamed up with the Canadian pharma on its hostile pursuit of Allergan. And this time, it's an investment in Sprout Pharmaceuticals--Valeant's latest pickup--that's bringing in the bucks.
Roche has been hot on the dealmaking trail this past year, snatching up smaller companies to boost its portfolio. In its latest round of M&A, the diagnostics giant is acquiring Kapa Biosystems, getting its hands on the company's next-generation sequencing (NGS) products to further build out its offerings.
Concept Life Sciences, a CRO pieced together through a string of acquisitions, has inked a deal to acquire a toxicology-focused contractor, looking to expand its palate of drug development services.